Leavell Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$859K Sell
35,669
-1,990
-5% -$52.1K 0.03% 346
2026
Q1
$1.06M Buy
37,659
+2,122
+6% +$56.5K 0.04% 305
2025
Q4
$885K Sell
35,537
-4,917
-12% -$124K 0.04% 314
2025
Q3
$1.03M Sell
40,454
-2,744
-6% -$67.7K 0.04% 296
2025
Q2
$1.05M Sell
43,198
-6,198
-13% -$145K 0.05% 293
2025
Q1
$1.25M Buy
49,396
+209
+0.4% +$5.47K 0.06% 258
2024
Q4
$1.3M Sell
49,187
-9,928
-17% -$269K 0.06% 248
2024
Q3
$1.71M Sell
59,115
-2,429
-4% -$70.9K 0.09% 219
2024
Q2
$1.72M Sell
61,544
-2,228
-3% -$61.3K 0.1% 198
2024
Q1
$1.77M Sell
63,772
-7,760
-11% -$215K 0.1% 191
2023
Q4
$2.06M Sell
71,532
-10,782
-13% -$326K 0.13% 161
2023
Q3
$2.73M Sell
82,314
-17,195
-17% -$608K 0.19% 124
2023
Q2
$3.65M Sell
99,509
-4,471
-4% -$174K 0.25% 106
2023
Q1
$4.24M Sell
103,980
-1,880
-2% -$81.2K 0.3% 88
2022
Q4
$5.42M Sell
105,860
-2,390
-2% -$115K 0.41% 72
2022
Q3
$4.74M Sell
108,250
-4,771
-4% -$232K 0.38% 79
2022
Q2
$5.93M Buy
113,021
+3,171
+3% +$162K 0.45% 69
2022
Q1
$5.69M Sell
109,850
-12
-0% -$623 0.39% 75
2021
Q4
$6.49M Buy
109,862
+339
+0.3% +$16.8K 0.43% 69
2021
Q3
$4.71M Buy
109,523
+3,284
+3% +$145K 0.35% 80
2021
Q2
$3.85M Hold
106,239
0.31% 97
2021
Q1
$3.85M Sell
106,239
-11,680
-10% -$415K 0.31% 97
2020
Q4
$4.34M Sell
117,919
-5,705
-5% -$209K 0.38% 76
2020
Q3
$4.3M Sell
123,624
-2,146
-2% -$75.2K 0.37% 76
2020
Q2
$3.9M Buy
125,770
+3,061
+2% +$104K 0.38% 80
2020
Q1
$3.8M Sell
122,709
-18,951
-13% -$646K 0.44% 69
2019
Q4
$5.27M Sell
141,660
-2,134
-1% -$76K 0.49% 60
2019
Q3
$4.9M Buy
143,794
+886
+0.6% +$32.2K 0.5% 57
2019
Q2
$5.87M Buy
142,908
+147
+0.1% +$5.84K 0.62% 42
2019
Q1
$5.75M Buy
142,761
+2,710
+2% +$109K 0.64% 40
2018
Q4
$5.8M Buy
140,051
+3,794
+3% +$157K 0.73% 35
2018
Q3
$5.7M Sell
136,257
-1,501
-1% -$57.8K 0.61% 42
2018
Q2
$4.74M Sell
137,758
-3,382
-2% -$116K 0.54% 50
2018
Q1
$4.75M Buy
141,140
+3,032
+2% +$104K 0.55% 51
2017
Q4
$4.75M Sell
138,108
-5,594
-4% -$191K 0.56% 49
2017
Q3
$4.87M Sell
143,702
-2,099
-1% -$67.5K 0.6% 48
2017
Q2
$4.65M Buy
145,801
+2,127
+1% +$67.1K 0.59% 50
2017
Q1
$4.66M Buy
143,674
+3,301
+2% +$104K 0.6% 43
2016
Q4
$4.33M Sell
140,373
-293
-0.2% -$8.95K 0.6% 43
2016
Q3
$4.52M Buy
140,666
+2,421
+2% +$81K 0.67% 37
2016
Q2
$4.62M Sell
138,245
-1,945
-1% -$62.1K 0.68% 37
2016
Q1
$3.94M Buy
140,190
+5,682
+4% +$162K 0.59% 43
2015
Q4
$4.12M Buy
134,508
+4,658
+4% +$147K 0.6% 35
2015
Q3
$3.87M Buy
129,850
+26,309
+25% +$844K 0.61% 33
2015
Q2
$3.29M Buy
103,541
+15,568
+18% +$507K 0.51% 52
2015
Q1
$2.9M Buy
87,973
+1,897
+2% +$60.3K 0.44% 66
2014
Q4
$2.54M Buy
86,076
+5,889
+7% +$169K 0.39% 75
2014
Q3
$2.25M Buy
80,187
+5,101
+7% +$143K 0.36% 87
2014
Q2
$2.11M Buy
75,086
+9,697
+15% +$276K 0.33% 95
2014
Q1
$1.99M Buy
65,389
+421
+0.6% +$12.6K 0.33% 93
2013
Q4
$1.89M Buy
64,968
+951
+1% +$27.7K 0.32% 96
2013
Q3
$1.75M Buy
64,017
+3,373
+6% +$91.8K 0.31% 90
2013
Q2
$1.61M Buy
+60,644
New +$1.68M 0.3% 90

Other funds holding PFE

Leavell Investment Management's PFE Position: Q2 2026 in Review

Leavell Investment Management reduced its Pfizer (PFE) stake by 5.3% in Q2 2026, selling an estimated $52.1K and leaving 35,669 shares worth $859K. The position accounts for 0.03% of the portfolio, ranked #346.

Leavell Investment Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.49M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Leavell Investment Management held 35,669 shares of Pfizer worth $859K as of Q2 2026.
  • Leavell Investment Management sold 1,990 Pfizer shares in Q2 2026, an estimated $52.1K.
  • Pfizer made up 0.03% of Leavell Investment Management's portfolio in Q2 2026, its #346 holding.
  • Leavell Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Leavell Investment Management's Pfizer position peaked at $6.49M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Leavell Investment Management's 13F filing for Q2 2026, filed 21 Jul 2026.